Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01962 |
| Species: | Homo sapiens |
| Position : | chr5:149631000-149636000 |
| Year: | 2022 |
| Title: | TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | breast carcinoma |
| PMID: | 34718356 |
| MONDO: | MONDO:0004989 |
| Tissue: | breast |
| Tissue Ontology ID: | UBERON:0000310 |
| Cell Source: | Human breast cancer cell |
| Cell Type: | malignant cell |
| Cell Ontology ID: | CL:0001064 |
| Experiment Type: | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| High Throughput Method: | ChIP-seq; RNA-seq; DNase-seq |
| Low Throughput Method: | Luciferase Reporter Assay; ChIP-RT-qPCR; CRISPR knockout; RT-RT-qPCR; Western blot |
| Target gene : | TCOF1 |
| TF name : | MYBL2 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| MYBL2 | E2F transcription factor network | pid | 77 |
| MYBL2 | G0 and Early G1 | reactome | 25 |
| MYBL2 | Polo-like kinase mediated events | reactome | 16 |
| MYBL2 | Hs_Gastric_Cancer_Network_1_WP2361_86831 | wikipathways | 26 |
| MYBL2 | Hs_EGF-EGFR_Signaling_Pathway_WP437_79266 | wikipathways | 107 |